Category Archives: People

The Carlyle Group Names John Kim as Managing Director of Asia Buyout Team

Carlyle

Seoul – Global alternative asset manager The Carlyle Group (NASDAQ: CG) today announced that John Kim will join the firm as a Managing Director of the Asia Buyout Team effective March 2020. Mr. Kim will lead Carlyle’s investment activities in Korea.

Joining from Goldman Sachs, where he served as Head of Mergers & Acquisitions in Asia ex-Japan, John brings more than 20 years’ experience in the financial industry. He previously served as the bank’s Co-Country Head of Korea and Head of Investment Banking in Korea and joined the firm in 2000 as an Executive Director for Corporate Finance in Seoul.

X.D. Yang, Managing Director and Chairman of Carlyle Asia, said, “John is an experienced leader in the region and has a wide range of experience working on significant transactions throughout Asia. We believe his background and deep understanding of the Korean market will help us position the business for the future and continue to create value for all of our stakeholders in the region.”

Greg Zeluck, Co-Head of the Asia Buyout team, said, “John joins at an exciting time for Carlyle in Korea. We see compelling opportunities, driven by restructurings within the corporate sector, multinationals and chaebols looking to divest non-core businesses, and generational changes. John will be a strong addition to the team as we continue to increase our investment in Korea.”

The Carlyle Group was one of the first global investment firms to establish a presence in Korea, having operated in the country for 20 years. As of June 30, 2019, the firm has invested more than US$1.5 billion of equity in Korea. Among the firm’s most recent and notable transactions has been its investment in ADT Caps, Korea’s second largest security services provider, and Yakjin Trading Corp, a major Korean apparel manufacturer.

About The Carlyle Group

The Carlyle Group (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across four business segments: Corporate Private Equity, Real Assets, Global Credit and Investment Solutions. With $223 billion of assets under management as of June 30, 2019, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. The Carlyle Group employs more than 1,775 people in 33 offices across six continents.

Web: www.carlyle.com

 

Media Contact:

The Carlyle Group
Tammy Li
Phone: +852 2878 5236
Email: tammy.li@carlyle.com

Categories: People

Kinnevik appoints Erika Söderberg Johnson as Chief Financial Officer

Kinnevik

1 Oct, 2019, 08:00 AM · Regulatory information

Kinnevik AB (publ) (“Kinnevik”), today announced that it has appointed Erika Söderberg Johnson as Chief Financial Officer. Erika Söderberg Johnson joins Kinnevik from Biotage where she has been CFO since 2012 and she will take up her position at the latest on 6 April 2020.

Georgi Ganev, CEO of Kinnevik, commented, “I am very pleased to welcome Erika to Kinnevik. She brings a wealth of experience including working as a CFO in fast growing listed medtech businesses, board work in Saab and Qliro Group and deep understanding of corporate finance from her early career in investment banking. I am confident that she will be a great addition to Kinnevik’s management team and add valuable insights to our portfolio companies.“

Prior to joining Biotage, Erika Söderberg Johnson was Chief Financial Officer at Karo Bio (2007-2011), Affibody (2005-2007) and Global Genomics (2002-2005) and she has been a board member of Sectra AB and MedCap AB. Erika Söderberg Johnson also worked ten years in Investment Banking and Corporate Finance at SEB Enskilda. She is a board member of publicly listed companies Saab AB (since 2017) and Qliro Group AB (since 2017). Erika Söderberg Johnson was born in 1970 and has a M.Sc. BA from Stockholm School of Economics.

For further information, visit www.kinnevik.com or contact:

Torun Litzén, Director Investor Relations
Phone +46 (0)70 762 00 50
Email press@kinnevik.com

Kinnevik is an industry focused investment company with an entrepreneurial spirit. Our purpose is to build the digital consumer businesses that provide more and better choice. We do this by working in partnership with talented founders and management teams to create, invest in and lead fast growing businesses in developed and emerging markets. We believe in delivering both shareholder and social value by building well governed companies that contribute positively to society. Kinnevik was founded in 1936 by the Stenbeck, Klingspor and von Horn families. Kinnevik’s shares are listed on Nasdaq Stockholm’s list for large cap companies under the ticker codes KINV A and KINV B.

Categories: People

Dyne Therapeutics announces appointment of Joshua Brumm as President and Chief Executive Office

Forbion

in portfolio news

Industry veteran brings extensive experience leading biotech companies through periods of growth.

WALTHAM, Mass.– Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced the appointment of Joshua Brumm as President and Chief Executive Officer.

“Josh brings extraordinary skills and experience to further our mission of creating life-transforming therapies for patients with serious muscle diseases,” said Jason Rhodes, partner with Atlas Venture and Dyne founder and executive chairman of the board of directors. “This positions us strongly to pursue the next phase of growth and product development, and we are thrilled to have him joining us.”

“Dyne’s FORCE therapeutic platform achieves a unique combination of tissue-specific delivery, high potency and tolerability to enable a broad product pipeline,” said Joshua Brumm. “I look forward to working closely with the board and talented team at Dyne to maximize the potential of our platform by advancing our pipeline and exploring new partnerships.”
“On behalf of everyone here, I am excited to welcome Josh,” said Romesh Subramanian, Dyne founder and chief scientific officer. “We look forward to working together to realize the therapeutic power of oligonucleotides for patients with rare muscle diseases and fulfilling Dyne’s mission.”

Prior to joining Dyne, Mr. Brumm served as chief operating officer and chief financial officer of Kaleido Biosciences, where he led the company’s financings including its initial public offering and helped bring the lead program into Phase 2 development. Prior to joining Kaleido, Mr. Brumm was COO and CFO at Versartis, where he oversaw the company’s financial strategy including the successful completion of its IPO, played an integral role in product strategy, and helped negotiate the company’s first product partnership. His previous roles include serving as executive vice president of finance and principal financial officer at Pharmacyclics; CFO at ZELTIQ Aesthetics, where he led the company through its initial public offering, led the international product launch for CoolSculpting and also served in corporate development; and director of finance at Proteolix, Inc., assisting in the sale of the company to Onyx Pharmaceuticals. He also held investment banking roles at Citigroup Global Markets, Inc. and Morgan Stanley. Over the course of his career, Mr. Brumm has raised approximately $1 billion in capital. In 2014, he was named Silicon Valley Business Journal’s CFO of the Year for companies under $500 million. He holds a B.A. in business administration from the University of Notre Dame.

About Dyne Therapeutics
Dyne Therapeutics is pioneering life-transforming therapies for patients with serious muscle diseases. The company’s FORCE™ platform delivers oligonucleotides and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision to restore muscle health. Dyne is advancing treatments for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). Dyne was founded in 2018 and is based in Waltham, Mass.

For more information, please visit www.dyne-tx.com.
Media Contact Ten Bridge Communications Max Stendahl, 508-277-8117 max@tenbridgecommunications.com

Categories: People

Tags:

Avedon Capital Partners expands team with appointment of Willem van der Veer

Avedon

Categories: People

Apiary Capital appoints new Investment Manager

Apiary Capital

Team-Jess.jpg

Apiary Capital is pleased to announce the appointment of Jessica French as Investment Manager.

Jess joins Apiary from boutique investment bank, Financo, having previously spent eight years at PwC, primarily in Corporate Finance advisory.

Jess’s appointment follows the successful close of Apiary’s £200m maiden fund last year, and the subsequent completion of the G3 Comms, Connect and Bertram Nursery Group investments earlier this year.

Mark Salter, Managing Partner at Apiary Capital commented, “Jess’s addition provides depth and breadth to our investment capability and we are delighted to welcome her to the Apiary team.”

Categories: People

n2 Biomedical Appoints Victor Nunes and Dean Schauer to Board of Directors

Bedford, MA – September 30, 2019: N2 Biomedical, a leading provider of proprietary surface treatment solutions and nanoscale coatings for implantable medical devices, today announced the appointments of Victor (“Vic”) Nunes and Dean Schauer to the Company’s Board of Directors. Nunes and Schauer join the Board following Ampersand Capital Partners’ majority recapitalization of the Company earlier this year. The transaction with Ampersand provided N2 Biomedical with an equity investment to fuel organic growth, expand the Company’s capabilities, and increase commercial sales efforts.

Mr. Nunes has over 25 years of medical device industry experience. He has served in a number of senior management and advisory roles in various medical device and life sciences companies, with a particular emphasis on orthopedics. Previous experience includes a variety of roles within DePuy Orthopedics, where he led integration of the $21 billion Synthes acquisition and assisted in the integration of DePuy Ace into Johnson & Johnson. Mr. Nunes also held Board positions at the Depuy Mitek and Codman Neuro divisions of J&J during his tenure as Senior Operations Executive. He has received advanced certifications from Duke University, the University of Virginia, and the University of Pennsylvania.

Mr. Schauer has served as President and CEO of Ampersand portfolio company Confluent Medical Technologies since 2013, and also joined Ampersand as an Operating Partner in 2016. Prior to Confluent, Mr. Schauer held a variety of executive leadership roles at Accellent, and was most recently Executive Vice President and General Manager of Accellent’s Cardiovascular Business. Prior roles at Accellent and its predecessors included EVP of Operations and Engineering, EVP of Sales and Marketing, and VP of Quality. Mr. Schauer holds a B.S. in Metallurgical Engineering from South Dakota Tech and is trained in Six Sigma methodology.

“Both Vic and Dean are proven, experienced executives within the medical device industry, and bring valuable insight to N2’s evolving growth strategy,” said Randall Sword, CEO of N2 Biomedical. “The additions to our Board come at an exciting time for N2 as we look to expand our service offering within medical end-markets. We welcome Vic and Dean’s experiences and guidance as we continue to build N2.”

About N2 Biomedical

Established in 2013, N2 provides coating and surface treatment development and application services for implantable and other medical devices utilized in orthopedic, cardiovascular, and other healthcare end-markets. N2 is ISO-13485 certified, FDA GMP-compliant, and operates in a 30,000 square foot facility with laboratory, manufacturing, and cleanroom space to service all customer and regulatory requirements. The company leverages its proprietary processes and equipment to provide customized solutions that enhance the characteristics of various materials in critical applications, including lubricity, infection resistance, biocompatibility and tissue integration, and wear and corrosion resistance. Additional information about N2 Biomedical is available at N2bio.com.

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of its core healthcare sectors, including Avista Pharma Solutions, Brammer Bio, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics, and Viracor-IBT Laboratories. Additional information about Ampersand is available at ampersandcapital.com.

Categories: People

The Carlyle Group Names Matt Anderson Chief Digital Officer and Stefan Grunwald Chief Procurement Officer

Carlyle

WASHINGTON – Global investment firm The Carlyle Group (NASDAQ: CG) today announced it has appointed two executives focused on driving value across its global portfolio. Matt Anderson, former President and Chief Digital Officer at Arrow Electronics, has been named Carlyle’s first Chief Digital Officer, and Stefan Grunwald, former Senior Vice President of Strategic Sourcing and Procurement at Cardinal Health, has been named Carlyle’s Chief Procurement Officer, effective today.

Both executives will deliver strategic and operational support to Carlyle’s portfolio companies and investment teams, working with the firm’s investment professionals and advisors including its Operating Executive and Senior Advisor consultants.

Anderson will develop and implement digital transformation strategies to help the firms in which Carlyle has invested grow and assist Carlyle’s investment teams in finding such opportunities during the diligence process. He will identify and execute new strategies in digital, data and analytics and other technologies, build an ecosystem of experts and suppliers, and play a leading role in CEO mentorship.

Grunwald will serve as the procurement and supply chain specialist for Carlyle’s portfolio and collaborate with management teams to identify and implement procurement and supply chain efficiency improvements. In addition, he will work with Carlyle’s investment teams to uncover procurement opportunities during due diligence.

Peter J. Clare, Co-Chief Investment Officer at The Carlyle Group, said, “The addition of Matt and Stefan to the Carlyle team underscores our commitment to creating value through operational improvement and to providing management teams with unrivaled tools and resources to grow.”

Clare continued, “With a proven track record of identifying and growing digital business opportunities, Matt is the right choice to help us find new, technology-driven ways to create near- and long-term impact. Stefan, an accomplished executive with 30 years of experience, will play an important role in helping our companies uncover value creation opportunities across their supply chains.”

Anderson said, “Carlyle’s growth-oriented investment approach is zeroing in on digital tools and resources as an important differentiator for its companies to unlock value, efficiencies and new business models. I look forward to partnering with some of the world’s most talented management teams, and to being part of the value-add that Carlyle brings to its investments.”

Grunwald said, “I am delighted to join Carlyle’s collaborative team and look forward to working closely with colleagues across the globe to facilitate procurement capabilities that generate positive results.”

Anderson, based in New York, brings a wealth of experience in both advising on and delivering digital transformations across a range of industries. Prior to Carlyle, he led the expansion of electronic components and computer products maker Arrow Electronics’ digital business. He led Arrow’s innovative partnership with Indiegogo, its expansion into cloud technology distribution, and launched an “on demand” engineering platform for high-tech design in the B2B space. Prior to Arrow, he led Booz & Co’s eCommerce and digitization practice and developed its digital transformation agency model before developing a digital business at UK-based yellow page and internet services company Hibu, formerly Yell Group. He holds Bachelor of Arts degrees in Economics and International Relations from the University of Pennsylvania.

Grunwald, based in Washington, D.C., brings a strong background leading enterprise-wide procurement transformations and managing teams from diverse functional and cultural backgrounds. Prior to Carlyle, he served as Senior Vice President of Strategic Sourcing and Procurement at healthcare services company Cardinal Health where he was accountable for Cardinal’s $10 billion Medical Device spend. Prior to that, he spent 19 years at Whirlpool Corporation in various leadership roles during which he managed teams in China, Brazil, Sweden and Italy. He holds a Bachelor of Science degree in Aerospace Engineering from Syracuse University.

* * * * *

About The Carlyle Group
The Carlyle Group (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across four business segments: Corporate Private Equity, Real Assets, Global Credit and Investment Solutions. With $223 billion of assets under management as of June 30, 2019, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. The Carlyle Group employs more than 1,775 people in 33 offices across six continents.

Contact
Christa Zipf
+1 (212) 813-4578
christa.zipf@carlyle.com

Categories: People

Anna Ljungdahl joins Industrifonden

Industriefonden

We’re pleased to welcome Anna Ljungdahl as Investment Manager. Anna will focus to drive Industrifonden’s deepening knowledge,- and potential investments in fintech, and evaluate and participate in investment opportunities created by technological innovation that contribute to build a sustainable society.

Anna brings extensive financial services experience following two decades of venture capital and finance experience at leading positions at SEB.

“With Anna’s extensive and long experience, we can now immerse ourselves in fintech, but also in other sectors where technology, societal impact and sustainability meet. I am excited to see what we can achieve next,” says David Sonnek, CEO of Industrifonden.

Read more about Anna here:

>Di Digital: Storbankschefen byter sida- ska investera i fintechbolag

Categories: People

Amira Oueld-El Hachemi joins Activa Capital

Activa Capital

Activa Capital, the French private equity firm, announces the recruitment of Amira Oueld-El Hachemi as Finance Department Analyst. This appointment is in line with Activa Capital’s development strategy, which aims to strengthen its Finance Department. Amira will manage the Activa Capital funds under the direction of Alexandre Chollet, Chief Finance Officer. Amira is a graduate of SKEMA Business School. She joins Activa Capital after prior experience at Essling Capital and Weinberg Capital Partners.

About Activa Capital

Activa Capital is an independent private equity company, owned by its partners, characterized by a proactive strategy of supporting growth (organic and external). It currently manages more than €500 million on behalf of institutional investors by investing in French SMEs and Mid-Caps with high growth potential and an enterprise value ranging between €20 million and €100 million. Activa Capital supports its portfolio companies to accelerate their development and international presence, often through active build-up programs.

To learn more about Activa Capital, visit activa capital.com

Press contacts

Alexandre Masson                                           Christophe Parier                                Christelle Piatto

Partner                                                             Partner                                                Communications Manager

+33 1 43 12 50 12                                           +33 1 43 12 50 12                               +33 1 43 12 50 12 alexandre.masson@activacapital.com             christophe.parier@activacapital.com  christelle.piatto@activacapital.com

Categories: People

Johan Hjertonsson assumes the position as CEO of Latour

Latour logo

In accordance with a previously published decision, Johan Hjertonsson assumed the position of President and CEO of Investment AB Latour (publ) on September 1, 2019. The decision was previously published through immediate publication on October 26, 2017.

Göteborg, September 2, 2019

INVESTMENT AB LATOUR (PUBL)
Olle Nordström
Chairman

For further information, please contact:
Olle Nordström, Chairman, +46 709 40 70 83

Investment AB Latour is a mixed investment company consisting primarily of a wholly-owned industrial operations and an investment portfolio of listing holdings in which Latour is the principal owner or one of the principal owners. The investment portfolio consists of nine substantial holdings with a market value of about SEK 57 billion. The wholly-owned industrial operations has an annual turnover of about SEK 12 billion.  

Categories: People